IOL Chemicals and Pharmaceuticals Full Year 2024 Earnings: Misses Expectations

Simply Wall St

August 07, 2024

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Full Year 2024 Results

Key Financial Results

Revenue: ₹21.3b (down 3.8% from FY 2023).
Net income: ₹1.34b (down 3.4% from FY 2023).
Profit margin: 6.3% (in line with FY 2023).
EPS: ₹22.90 (down from ₹23.70 in FY 2023).

revenue-and-expenses-breakdown — NSEI:IOLCP Revenue and Expenses Breakdown August 7th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

IOL Chemicals and Pharmaceuticals Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 28%.

The primary driver behind last 12 months revenue was the Pharmaceutical segment contributing a total revenue of ₹12.6b (59% of total revenue). Notably, cost of sales worth ₹14.2b amounted to 67% of total revenue thereby underscoring the impact on earnings.Explore how IOLCP's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India.

Performance of the Indian Pharmaceuticals industry.

The company's shares are down 5.8% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with IOL Chemicals and Pharmaceuticals, and understanding it should be part of your investment process.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com